Breast Cancer Clinical Trial
— BRECOROfficial title:
The Breast Cancer Online Rehabilitation Program: A Feasibility Study of Individually Tailored Online Rehabilitation After Breast Cancer Surgery The Copenhagen BRECOR Program
NCT number | NCT02673918 |
Other study ID # | CCCH-UBC 01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2016 |
Est. completion date | June 2017 |
Verified date | November 2019 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators have developed an online rehabilitation platform to guide women in their
home-based upper-body exercises after breast cancer surgery. The platform includes
rehabilitation videos that will guide the women in performing home-based early post-surgery
upper-body rehabilitation tailored for each individual.
The primary objective is to assess the feasibility and acceptability of a home-based
rehabilitation program supported by a supplemental online platform for women after breast
cancer surgery before conducting a larger pragmatic trial in the future. The feasibility of
the platform will be tested in 11 municipalities in Denmark.
Status | Completed |
Enrollment | 59 |
Est. completion date | June 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of breast cancer - Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection), including those women with a history of previous surgery for breast cancer, radiation therapy or chemotherapy - Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks. - Home access to internet from stationary computer, lab top or tablet - Ability to use internet - Ability to read and understand Danish Exclusion Criteria: - Surgery for breast cancer with immediate breast reconstruction - Diagnosis of primary lymphedema - Metastatic or inflammatory breast cancer - Planned use of chemotherapy within the next 6 weeks - Surgical complications: infection, drainage issues, seroma, hematoma - Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol: i.e. severe depression, anxiety, dementia, poor physical health with likely possibility of hospitalization within the next twelve weeks. - Planned hospitalization or surgery within the next twelve weeks - Participation in another clinical trial with a rehabilitation or exercise intervention |
Country | Name | City | State |
---|---|---|---|
Denmark | Tranehaven | Charlottenlund | |
Denmark | Copenhagen Centre for Cancer and Health | Copenhagen | |
Denmark | Sundhedscenter Frederiksberg | Frederiksberg | |
Denmark | Lukas | Hellerup | |
Denmark | Træningscenteret Møllebo | Lyngby | |
Denmark | Furesø Kommunes Genoptræningscenter | Værløse |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment Rate | This outcome represent the number and proportion (%) of eligible patients who consented to participate in the study. Recruitment was open for 10 weeks for participants in Part 1 and for 20 weeks for participants in Part 2. | 10 weeks for part 1 and 20 weeks for part 2 | |
Primary | Retention | Participants who are enrolled in the study but fail to complete the end of study assessment will be recorded as dropouts. Feasibility will be defined as a drop out of <10% | 12 weeks | |
Primary | Number of Participants Reporting Being "Very Satisfied" or "Somewhat Satisfied" With the Program | At the end of the study data describing participant satisfaction will be collected to answers questions on acceptability. All participants in part 1 and part 2 will be given a questionnaire, delivered by Easy Research, and will be asked to rank various aspects of the intervention such as the home-based exercises supported by videos, mode of delivery, software, etc. "as not at all satisfied", "not very satisfied", "somewhat satisfied" or "very satisfied". Feasibility will be defined as >75% of participants reporting they are "very" or "somewhat satisfied" with the intervention. | 12 weeks | |
Primary | Capacity/ Resources | The amount of time spent with each participant during the standard upper-body assessments, instruction of the home-based intervention and assistance needed with using the website during the study period will be tracked. In addition, any additional appointments required to teach the home-based rehabilitation program or to assist in using the website will be recorded. This information will help to determine the resources needed to administer the online component of the home-based program on a larger scale to a broader group of participants. This data was only collected for Part 1. | 12 weeks | |
Primary | Adherence | Participants in part 1 and part 2 were asked to perform the rehabilitation program at least four times weekly for the duration of the study (12 weeks). Adherence was calculated as the number and proportion of participants who reported in a follow-up questionnaire that they had performed four or more weekly sessions. As such, participants who reported to have completed the home-based rehabilitation program 4 times per week were categorized as having adhered to the program. Likewise, participants who reported to have completed the program 3 times or fewer per week were categorized as not having adhered to the program. | 12 weeks | |
Secondary | Motivation for Rehabilitation Exercises | To answers questions on motivation, the participants' reaction to the intervention, intend to use, and perceived appropriateness of the rehabilitation exercises will be answered. Behavioral changes in motivation to do home-based rehabilitation exercises will be measured as this is fundamental to adherence. The study method is theoretically based in the framework of Theory of Planned Behavior and has been validated in measuring motivation for exercise among cancer survivors including breast cancer patients. The Intention, Attitude and Subjective Norm Questionnaire is a 19-item Theory of Planned Behavior questionnaire modified for use with online home-based rehabilitation. All questions are answered using a 7 point Likert scale and produces effect sizes (Cohen's D). The Theory of Planned Behavior scale is scored on a 0 to 7 scale with a higher score indicating a greater level of motivation. | 12 weeks | |
Secondary | Clinical Outcomes in Upper-body Function: Mobility | Active shoulder mobility for flexion and external rotation. Changes from baseline to follow-up (12 weeks later) will be calculated. This data was only collected for participants in part 1. | 12 weeks | |
Secondary | Clinical Outcomes in Upper-body Function: Muscle Strength | Upper body muscle strength was tested using Manual Muscle Testing among participants in part 1 only. | 12 weeks | |
Secondary | Clinical Outcomes in Upper-body Function: Arm Circumference | Arm circumference at 5 points along the arm. Changes from baseline will be calculated. | 12 weeks | |
Secondary | Clinical Outcomes in Upper-body Function: Pain | Patient-reported pain on a 0-10 Visual Analogue Scale in the breast/arm region. A higher score indicates greater level of pain. Changes from baseline will be calculated. This data was only collected for part 1. | 12 weeks | |
Secondary | Ability to Perform Activities of Daily Living | QuickDASH (Disabilities of the Arm, Shoulder, and Hand) scores 0 to 100 with higher scores indicating more limitations in upper-body functioning. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |